1. Home
  2. ENTX vs AXTI Comparison

ENTX vs AXTI Comparison

Compare ENTX & AXTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • AXTI
  • Stock Information
  • Founded
  • ENTX 2010
  • AXTI 1986
  • Country
  • ENTX Israel
  • AXTI United States
  • Employees
  • ENTX N/A
  • AXTI N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • AXTI Semiconductors
  • Sector
  • ENTX Health Care
  • AXTI Technology
  • Exchange
  • ENTX Nasdaq
  • AXTI Nasdaq
  • Market Cap
  • ENTX 104.0M
  • AXTI 84.8M
  • IPO Year
  • ENTX 2018
  • AXTI 1998
  • Fundamental
  • Price
  • ENTX $1.86
  • AXTI $2.35
  • Analyst Decision
  • ENTX Strong Buy
  • AXTI Strong Buy
  • Analyst Count
  • ENTX 1
  • AXTI 4
  • Target Price
  • ENTX $10.00
  • AXTI $4.64
  • AVG Volume (30 Days)
  • ENTX 40.5K
  • AXTI 459.6K
  • Earning Date
  • ENTX 08-08-2025
  • AXTI 07-31-2025
  • Dividend Yield
  • ENTX N/A
  • AXTI N/A
  • EPS Growth
  • ENTX N/A
  • AXTI N/A
  • EPS
  • ENTX N/A
  • AXTI N/A
  • Revenue
  • ENTX $223,000.00
  • AXTI $96,029,000.00
  • Revenue This Year
  • ENTX N/A
  • AXTI N/A
  • Revenue Next Year
  • ENTX N/A
  • AXTI $28.89
  • P/E Ratio
  • ENTX N/A
  • AXTI N/A
  • Revenue Growth
  • ENTX N/A
  • AXTI 21.44
  • 52 Week Low
  • ENTX $1.41
  • AXTI $1.13
  • 52 Week High
  • ENTX $2.79
  • AXTI $3.77
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 44.39
  • AXTI 55.16
  • Support Level
  • ENTX $1.91
  • AXTI $2.28
  • Resistance Level
  • ENTX $2.04
  • AXTI $2.55
  • Average True Range (ATR)
  • ENTX 0.10
  • AXTI 0.18
  • MACD
  • ENTX 0.00
  • AXTI -0.02
  • Stochastic Oscillator
  • ENTX 37.84
  • AXTI 48.08

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About AXTI AXT Inc

AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.

Share on Social Networks: